ArticleAnnals of gastroenterology
Serum anti-integrin αvβ6 autoantibodies for diagnosis of primary sclerosing cholangitis: a systematic review and meta-analysis.
Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comments on modeling strategy and data handling in a meta-analysis of anti-integrin αvβ6 for primary sclerosing cholangitis.Annals of gastroenterologyArticle
- Authors' reply.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, there is no noninvasive serological marker for primary sclerosing cholangitis (PSC). Serum anti-integrin αvβ6 autoantibodies were recently suggested as potential diagnostic PSC biomarkers. We conducted a systematic review and meta-analysis to evaluate their diagnostic performance, the influence of concomitant inflammatory bowel disease (IBD), and differentiation from other cholestatic liver diseases. Methods: PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched for studies assessing the diagnostic value of serum anti-αvβ6 autoantibodies in PSC. Pooled sensitivity, specificity, diagnostic odds ratio and area under the summary receiver operating characteristic curve (AUC) were calculated using a bivariate random-effects model. Subgroup analyses were performed based on IBD status and differentiation from other cholestatic liver diseases. Results: Four studies including 1294 subjects (398 PSC patients and 896 controls) were analyzed. The pooled sensitivity and specificity of anti-αvβ6 autoantibodies for PSC diagnosis were 62.3% and 87.3%, respectively (AUC: 0.76). The specificity increased to 96% (AUC: 0.86) in PSC without IBD, while it decreased to 71% (AUC: 0.67) in PSC with IBD. For the differentiation of PSC from other cholestatic liver diseases, anti-αvβ6 autoantibodies had pooled sensitivity 81% and specificity 95% (AUC: 0.90). Conclusions: Serum anti-αvβ6 autoantibodies exhibit moderate sensitivity and high specificity for PSC diagnosis, especially in differentiation from other cholestatic diseases. Their clinical utility as a noninvasive diagnostic biomarker is promising and warrants validation in larger, multicenter prospective studies to establish their role in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.